Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hormozgan University of Medical Sciences |
---|---|
Information provided by: | Hormozgan University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT00432588 |
Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).
Condition | Intervention | Phase |
---|---|---|
Preeclampsia Fetal Death Fetal Membranes, Premature Rupture |
Drug: misoprostol Drug: dinoprostone |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Genders Eligible for Study: | Female |
Inclusion Criteria:
Exclusion Criteria:
Iran, Islamic Republic of | |
Shariaty Maternity Hospital | |
Tehran, Iran, Islamic Republic of |
Principal Investigator: | Mitra Ahmad Soltani | Hormozgan University of Medical Sciences |
Study Chair: | Minoo Rajaee Lari, Perinatologist - Obs and Gyn | Department of Obs and Gyn - HUMS |
Study ID Numbers: | Misoprostol vs Dinoprostone |
Study First Received: | February 6, 2007 |
Last Updated: | May 31, 2007 |
ClinicalTrials.gov Identifier: | NCT00432588 |
Health Authority: | United States: Food and Drug Administration |
IUFD POSTTERM ROM |
Death Pregnancy Complications Eclampsia Misoprostol Obstetric Labor Complications Pre-Eclampsia Rupture |
Fetal Membranes, Premature Rupture Preeclampsia Fetal Death Dinoprostone Hypertension, Pregnancy-Induced Pregnancy toxemia /hypertension Hypertension |
Pathologic Processes Oxytocics Therapeutic Uses Anti-Ulcer Agents Abortifacient Agents |
Physiological Effects of Drugs Gastrointestinal Agents Reproductive Control Agents Abortifacient Agents, Nonsteroidal Pharmacologic Actions |